Biologix is a Dubai-based firm that represents international pharma companies by bringing innovative drugs to market in the Middle East / North Africa (MENA) region. Its GM, Zeina Sfeir Lahoud, discusses the company’s presence in over 17 countries, their 25 years of experience in Saudi Arabia, and the dynamics shaping the largest market in the region, including the fast regulatory approval process in place. With value-based healthcare an increasingly hot topic, she explains how Biologix has moved to sign the first risk-sharing agreement with Saudi Arabia for a spinal muscular atrophy product; the first in the MENA region.
STAY UP TO DATE NEWS & EVENTS
Related EVENTS & NEWS
Oman Genetic & Genomics Congress 2022
Biologix team attended the Oman Genetic & Genomics Congress at Hormuz Grand Muscat, Oman from 29th till 30th of September. Read More ...
Launching the first national program for SMA in Egypt

